Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (отваря нов прозорец)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Източник‎: Br J Haematol 2013;161(5):738-40.

Статията е индексирана‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (отваря нов прозорец)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (отваря нов прозорец)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Източник‎: Haematologica 2021;106(4):1148-57.

Статията е индексирана‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (отваря нов прозорец)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (отваря нов прозорец)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Източник‎: Cancer 2008;113(6):1338-43.

Статията е индексирана‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (отваря нов прозорец)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (отваря нов прозорец)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Източник‎: Transfusion 2012;52(4):739-41.

Статията е индексирана‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (отваря нов прозорец)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (отваря нов прозорец)

Bhatia M, Davenport V, Cairo MS.

Източник‎: Leuk Lymphoma 2007;48(1):9-15.

Статията е индексирана‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (отваря нов прозорец)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (отваря нов прозорец)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Източник‎: BMC Cancer 2013;13:121.

Статията е индексирана‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (отваря нов прозорец)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (отваря нов прозорец)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Източник‎: Pathol Oncol Res 2011;17(1):141-3.

Статията е индексирана‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (отваря нов прозорец)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (отваря нов прозорец)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Източник‎: J Neurooncol 2012;106(2):427-9.

Статията е индексирана‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (отваря нов прозорец)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (отваря нов прозорец)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Източник‎: Lancet 2003;361(9354):275-80.

Статията е индексирана‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (отваря нов прозорец)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (отваря нов прозорец)

Ford PA, Grant SJ, Mick R, Keck G.

Източник‎: J Clin Oncol 2015;33(15):1674-9.

Статията е индексирана‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (отваря нов прозорец)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (отваря нов прозорец)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Източник‎: Platelets. 2022 3;33(7):1024-1030.

Статията е индексирана‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (отваря нов прозорец)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (отваря нов прозорец)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Източник‎: Cancer 2014;120(12):1838-46.

Статията е индексирана‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (отваря нов прозорец)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (отваря нов прозорец)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Източник‎: Leuk Lymphoma 2013;54(2):321-8.

Статията е индексирана‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (отваря нов прозорец)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (отваря нов прозорец)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Източник‎: Platelets 2012;23(6):423-9.

Статията е индексирана‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (отваря нов прозорец)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (отваря нов прозорец)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Източник‎: Ann Hematol 2015;94(1):117-28.

Статията е индексирана‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (отваря нов прозорец)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (отваря нов прозорец)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Източник‎: J Hematol Oncol 2015;8:37.

Статията е индексирана‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (отваря нов прозорец)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (отваря нов прозорец)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Източник‎: J Clin Oncol 2010;28(3):437-44.

Статията е индексирана‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (отваря нов прозорец)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (отваря нов прозорец)

Locantore-Ford P, Grant SJ, Keck G.

Източник‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (отваря нов прозорец)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (отваря нов прозорец)

Loo M, Beguin Y.

Източник‎: Blood 1999;93(10):3286-93.

Статията е индексирана‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (отваря нов прозорец)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (отваря нов прозорец)

Miao J, Leblebjian H, Scullion B, Parnes A

Източник‎: Am J Hematol 2018;93(4):E86-E88.

Статията е индексирана‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (отваря нов прозорец)

Pharmacological therapies to minimise platelet transfusion. (отваря нов прозорец)

Norfolk DR, Seghatchian J.

Източник‎: Transfus Sci 2000;22(3):149-53.

Статията е индексирана‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (отваря нов прозорец)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (отваря нов прозорец)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Източник‎: Support Care Cancer 2014;22(5):1217-22.

Статията е индексирана‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (отваря нов прозорец)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (отваря нов прозорец)

Pathak S, Roth M, Verma A, Steidl U.

Източник‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Статията е индексирана‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (отваря нов прозорец)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (отваря нов прозорец)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Източник‎: Leuk Lymphoma. 2019;60(9):2324-7.

Статията е индексирана‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (отваря нов прозорец)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (отваря нов прозорец)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Източник‎: Lancet Haematol 2015;2(10):e417-26.

Статията е индексирана‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (отваря нов прозорец)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (отваря нов прозорец)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Източник‎: Am J Blood Res 2013;3(3):260-4.

Статията е индексирана‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (отваря нов прозорец)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (отваря нов прозорец)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Източник‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Статията е индексирана‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (отваря нов прозорец)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (отваря нов прозорец)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Източник‎: Blood 2010;116(12):2127-33.

Статията е индексирана‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (отваря нов прозорец)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (отваря нов прозорец)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Източник‎: Blood 2012;120(2):386-94.

Статията е индексирана‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (отваря нов прозорец)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (отваря нов прозорец)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Източник‎: Cancer 2011;117(5):992-1000.

Статията е индексирана‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (отваря нов прозорец)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (отваря нов прозорец)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Източник‎: J Clin Oncol 2019;37(31):2892-8.

Статията е индексирана‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (отваря нов прозорец)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (отваря нов прозорец)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Източник‎: Blood 2000;95(9):2983-9.

Статията е индексирана‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (отваря нов прозорец)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (отваря нов прозорец)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Източник‎: Eur J Haematol 2014;93(5):439-45.

Статията е индексирана‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (отваря нов прозорец)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (отваря нов прозорец)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Източник‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Статията е индексирана‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (отваря нов прозорец)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (отваря нов прозорец)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Източник‎: Ann Oncol 2005;16(1):139-45.

Статията е индексирана‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (отваря нов прозорец)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (отваря нов прозорец)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Източник‎: J Hematol Oncol 2012;5:71.

Статията е индексирана‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (отваря нов прозорец)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (отваря нов прозорец)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Източник‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Статията е индексирана‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (отваря нов прозорец)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (отваря нов прозорец)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Източник‎: Blood 2009;114(18):3899-908.

Статията е индексирана‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (отваря нов прозорец)